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STUDY SUMMARY 
 
Phase 2 Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV 
 
Study 9780 
 
Design:  Phase 2, multi-center, fully-masked, randomized, parallel, placebo-
controlled effectiveness and extended safety study to assess the 
role of TDF as prophylaxis to prevent HIV acquisition 
 
Population:  1,200 HIV antibody negative participants: 
  600 participants will use TDF daily 
  600 participants will use placebo daily 
 
Study Duration:  6 months screening, 6 months recruitment, 12 months of product 
use for each participant, 20 months in the field, including screening 
and close-down 
 
Primary Objectives:    Determine the effectiveness and safety of daily use of 300 mg TDF 
for HIV prevention 
 
Primary Endpoints:   Incidence of HIV-1 and HIV-2 infection as determined by 
detection of HIV antibodies from oral mucosal transudate (OMT) 
specimens and confirmation by ELISA. 
 
        Incidence of liver and kidney events as determined by AST and 
ALT for hepatic function, and serum creatinine and phosphorus for 
kidney function. 
 
Study Sites:       Douala, Cameroon 
        Ibadan, Nigeria 
        Tema, Ghana  
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LIST OF ABBREVIATIONS AND ACRONYMS 
 
AE         adverse event 
AIDS        acquired immunodeficiency syndrome 
ALT (SGPT)      alanine aminotransferase 
AST (SGOT)      aspartate aminotransferase 
DCF        data collection forms 
DMC         Data Monitoring Committee 
eDCF        electronic data collection form 
ELISA       enzyme-linked immunosorbent assay 
FDA         (U.S.) Food and Drug Administration 
g         gram(s) 
GCP         Good Clinical Practice guidelines 
HAART       highly active antiretroviral therapy 
HIV-1        human immunodeficiency virus type 1 
HIV-2        human immunodeficiency virus type 2 
ICH         International Conference of Harmonisation 
IRB         Institutional Review Board 
ITT         intent-to-treat 
IU        international units 
kg         kilogram(s) 
LLN         lower limit of the normal range 
LLOQ        lower limit of quantification 
mg         milligram(s) 
mL         milliliter(s) 
mm3         cubic millimeter(s) 
NNRTI       non-nucleoside reverse transcriptase inhibitor 
NRTI        nucleoside reverse transcriptase inhibitor 
NtRTI        nucleotide reverse transcriptase inhibitor 
OMT        oral mucosal transudate 
PCR         polymerase chain reaction 
PharmaLinkFHI    a contract research organization responsible for data management 
PrEP        pre-exposure prophylaxis 
RT         reverse transcriptase 
SAE         serious adverse event 
TDF         tenofovir disoproxil fumarate, GS-4331-05, PMPA prodrug 
µg         microgram 
ULOQ       upper limit of quantification 
ULN         upper limit of the normal range 
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1.  INTRODUCTION 
1.1  Background 
 
The HIV epidemic is continuing to grow worldwide.  An effective, easy to use method of 
prevention is urgently needed.  Consistent and correct condom use is the only method currently 
recommended for prevention of sexually transmitted HIV. Vaginal microbicides are being 
developed in the hopes of offering women a method to protect themselves from infection when 
condom use is not possible.  However, no vaginal microbicide candidate has shown effective 
protection from HIV in human trials. 
 
TDF is an orally bioavailable prodrug of tenofovir, an acyclic nucleotide analog with activity in 
vitro against retroviruses, including HIV-1, HIV-2, and hepadnaviruses.
1 
 
The non-clinical toxicology of TDF has been studied in mice, rats, rabbits, and dogs.  The 
principal target organs of toxicity following oral administration of TDF were the gastrointestinal 
tract, kidney, and bone.
2 
 
The safety profile of TDF is primarily derived from clinical studies.  There has been no evidence 
of renal toxicity related to TDF.  Laboratory evaluation of serum creatinine and phosphorus has 
not demonstrated a difference between TDF and placebo or other active controls.
2 
 
Evidence suggests that oral, once-daily TDF 300 mg appears comparable to placebo for safety 
and has durable efficacy in HIV-1-infected patients with high levels of baseline resistance to 
nucleoside reverse transcriptase inhibitors.  The FDA has approved 300 mg TDF per day as safe 
and effective for treatment for HIV infection.  TDF has received marketing approval in the 
European Union.  No marketing authorizations have been withdrawn or suspended, and no 
marketing authorizations have been denied. No clinical trials have been suspended, there have 
been no dosage modifications since approval, and no changes in target populations, labeling, or 
formulation changes for safety reasons since approval.
2 
 
Furthermore, animal studies provide strong support for both the pre-exposure as well as post-
exposure efficacy of TDF in preventing retroviral infections. These studies include challenge by 
both the intravenous and intravaginal modes of SIV infection as well as vertical transmission to 
neonate macaques. 
 
Tenofovir was found to have potent activity in an acute challenge experiment of simian 
immunodeficiency virus (SIV) infection in monkeys, a model of needlestick injury.  When 
treatment was started as late as 24 hours after intravenous SIV inoculation and continued for four 
weeks, tenofovir was found to completely protect the animals from SIV infection without signs 
of toxicity.
3 
 
By intravaginal administration topically, tenofovir also was completely protective against 
vaginal transmission of SIV in another simian model.  Such activity of an antiviral compound in  
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animal models is unprecedented and makes tenofovir a promising agent for both treatment and 
prevention of HIV infection.
4 
 
The safety of TDF has been established with regard to its use in combination with other 
antiretrovirals for HIV-infected persons.  However, the safety profile for healthy, uninfected 
persons or for uninfected persons with conditions such as malaria has not been established.   
 
This Phase 2 study will evaluate the effectiveness of TDF 300 mg as an HIV prevention method 
when taken once a day.  This Phase 2 study in three countries will provide extended safety data 
for high-risk populations in those countries.  The daily tablet of TDF will allow disassociation of 
the preventive method from the type of coitus (wet vs. dry), number of coital acts, the timing of 
the coitus, the place of coitus, or other sexual activity such as anal or oral sex.   
 
We will study the effectiveness and safety of TDF in a population of young women at high-risk 
for HIV infection. 
1.2  Rational 
 
TDF has been selected for investigation as prophylaxis against HIV in high-risk young women 
because of its unique pharmacologic profile.  In addition to the convenience of being a once 
daily single tablet, TDF’s safety profile is comparable to placebo among HIV infected persons, it 
has striking anti-HIV potency, and it has low potential for selection of resistant viruses.  TDF is 
cleared from the body by the kidneys and is not metabolized by the liver.  Therefore, TDF has 
limited potential to have pharmacokinetic interactions with other hepatically metabolized drugs.  
Each of these properties is necessary given the realities of the intended target populations.  
Moreover, initial prevention studies in simian models have provided encouraging results.  
Finally, the drug’s sponsor, Gilead Sciences, is supportive of investigating the potential use of 
TDF as a preventive, as well as therapeutic, agent and will provide TDF for the study.  Gilead 
also is willing to make a good faith effort to make TDF available for public health use should it 
prove to be effective for HIV prevention. 
 
Condoms and potential vaginal microbicides require consistent and correct use during every 
coital act.  This is similar to the situation when barrier methods were the most common forms of 
nonpermanent contraception.  However, when hormonal oral contraceptives were introduced and 
the preventive method became disassociated with coitus, contraception become easier, popular, 
and more effective at the individual and population level.  If successful, this drug has the 
potential to do for HIV prevention what oral contraceptives did for pregnancy prevention.  
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2.  STUDY OBJECTIVES 
2.1  Primary Objectives 
 
·  To assess the effectiveness of TDF 300 mg use by young women at high risk for HIV in 
countries that will be suitable for the introduction of TDF as a preventive intervention 
·  To assess the extended safety of TDF 300 mg per day among women who are not HIV 
infected 
 
Comparing the HIV incidence in the TDF group with that in the control group will assess 
effectiveness. 
 
Comparing data on changes in kidney and liver function, as well as the frequency of adverse 
events in the TDF group with that in the control group will assess extended safety. 
3.  TRIAL DESIGN 
 
This Phase 2 clinical trial will be conducted in compliance with the protocol, FHI SOPs, Good 
Clinical Practices (ICH/GCP), and the applicable regulatory requirements of the FDA and the 
site countries. 
3.1  Primary Endpoints 
 
The effectiveness endpoint is conversion for antibodies to HIV 1 or 2 as determined by an OMT 
test and confirmed by an ELISA from a finger prick specimen.  Discordant results between the 
OMT and the ELISA will be tested with Western blot. 
 
Laboratory safety endpoints will include serum creatinine and phosphorus for kidney function, 
and AST and ALT for hepatic function.  Reported adverse events will also be used for clinical 
evaluation of safety. 
3.2  Study Design  
 
This protocol describes a multi-center, randomized, fully-masked, parallel, placebo-controlled 
study of TDF for pre-exposure prophylaxis of HIV in high-risk women.   
 
One thousand two hundred women from Douala, Cameroon, Ibadan, Nigeria and Tema, Ghana 
will be randomized 1:1 to once daily use of TDF 300 mg or placebo.  Each country will 
contribute 400 participants to the study.  Recruitment of participants will take about 6 months 
and each participant will be followed for 1 year. 
 
HIV status will be monitored monthly.  Participants will be monitored for safety using periodic 
physical examinations, serial laboratory tests, and adverse event queries.  
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In order to provide sufficient information for early safety monitoring, we will conduct laboratory 
tests for kidney and liver function at screening and then at months 1, 3, and then every 3 months 
thereafter or at their final visit if they withdraw early.   
 
To minimize their risk of contracting HIV infection, women will be counseled monthly to use 
male condoms every time they have intercourse.  Male latex condoms will be provided to 
participants.  Participants converting for antibodies to HIV will be counseled and referred to 
medical services as appropriate for each country.  ￿
3.3  Measures to Minimize Bias 
3.3.1  Randomization 
 
The Randomization Manager who is not otherwise involved with the study will develop the 
allocation sequence using a computer random number generator and randomly varied permuted-
blocks.  Participants will be assigned their randomization number only after they have qualified 
for the study and signed the consent form.  Randomization will be stratified by study site. 
3.3.2  Allocation concealment  
 
Individual assignments will be concealed in sequentially numbered, sealed opaque envelopes.  
Trained staff will open the envelopes only after participants are properly consented and enrolled.  
The randomization envelopes will be maintained in a secure office. They will not be available to 
the study counselors until the immediate moment of randomization.  Each randomization 
envelope will be used only once and maintained in the participant’s study files. 
3.3.3  Masking 
 
Placebo tablets to match the TDF tablets are available, and contain denatonium benzoate to 
provide a bitter taste to resemble the active tablets.  The participants, field study staff, monitors, 
statisticians, and FHI staff actively involved in the trial will not know which participants are 
using TDF and which are using placebo. 
3.3.4  Decoding procedure 
 
The FHI Randomization Manager will keep the randomization code.  The Manager will provide 
the code to the FHI Study Clinician if needed to reveal the masking to the Investigator for 
emergencies.  The Manager will provide the code to the DMC during meetings to review the 
interim data.  The Manager will provide the code to the statisticians when they are prepared to 
unmask the code after completion of the final masked analysis of the data. 
3.4  Study Product 
 
Tenofovir (PMPA), 9-[(R)-2-(phosphonomethoxy)propyl] adenine monohydrate) is an acyclic 
nucleotide analog with activity in vitro against retroviruses, including HIV-1 and HIV-2. 
Tenofovir is metabolized intracellularly to tenofovir diphosphate (PMPApp), which is a  
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competitive inhibitor of HIV-1 reverse transcriptase (RT) that terminates the growing DNA 
chain. 
 
Due to the presence of a phosphonate group, tenofovir has limited oral bioavailability.  Tenofovir 
disoproxil fumarate (tenofovir DF, (9-[(R)-2-[[bis[[(isopropoxycarbonyl)oxy]  
methoxy]phosphinyl]methoxy] propyl] adenine fumarate)) is a prodrug of tenofovir.  Tenofovir 
DF (TDF) is orally bioavailable in animals and humans and is rapidly converted to tenofovir 
following absorption. 
 
Treatment-Related Adverse Events (Grades 1-4) Reported in >3% of VIREAD-Treated Patients 
in the Pooled 902 - 907 Studies (0-24 weeks)
5 
 
  VIREAD 
300 mg 
Placebo 
 
Number of patients treated  443  210 
Nausea  11%  10% 
Diarrhea  9%  8% 
Asthenia  8%  8% 
Headache  6%  7% 
Vomiting  5%  2% 
Flatulence  4%  0% 
Abdominal Pain  3%  3% 
Anorexia  3%  1% 
 
Grade 3/4 Laboratory Abnormalities Reported in ￿ 1% of VIREAD-Treated Patients in the 
Pooled 902 - 907 Studies (0-24 weeks)
5 
 
  VIREAD 
300 mg 
Placebo 
 
Number of patients treated  443  210 
Number of patients with Grade 3 or 4 
laboratory abnormalities 
117 (26%)  78 (37%) 
Laboratory abnormalities     
    Triglyceride (>750 mg/dl)  37 (8%)  28 (13%) 
    Creatine Kinase (>782 U/L)  53 (12%)  38 (18%) 
    Serum amylase (>175 U/L)  21 (5%)  14 (7%) 
    AST 
        Male >180 U/l 
        Female >170 U/L 
 
16 (4%) 
 
6 (35) 
    Urine glucose (3+ or 4+)  12 (3%)  6 (3%) 
    ALT elevation 
        Male >215 U/L 
        Female >170 U/L 
 
10 (2%) 
 
4 (2%) 
    Serum glucose >250 mg/dL  8 (2%)  8 (4%) 
    Neutrophil <650/mm
3  6 (1%)  3 (1%) 
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3.5  Duration of the Study 
 
The study is expected to last a total of 20 months at each site.  Enrollment of participants will 
take 6 months.  Each individual participant will be followed for 12 months.  Screening will start 
1 month before enrollment.  The study will remain open for 1 month after the last scheduled 
follow-up visit to allow follow-up on ongoing AEs and attempts to find participants that have not 
returned for their scheduled visits. 
3.6  Withdrawal Criteria 
3.6.1  Individual participants 
 
Participants withdrawn will not be replaced.  A participant may be withdrawn early from the 
study for any of the following reasons: 
 
·  She considers it to be in her best interest 
·  A physician considers it to be in the participant' s best interest because of safety reasons 
and/or for the well-being of the participant 
 
Reasons for withdrawal from the study (and study product) will be recorded on the appropriate 
DCF.  When early withdrawal from the study occurs, every reasonable effort will be made 
to assess information relevant to the primary endpoints at the time of discontinuation.  This 
would include attempts to obtain specimens for HIV testing. 
 
TDF is rated for use in pregnancy as category B: reproduction studies have been performed in 
rats and rabbits at doses up to 14 and 19 times the human dose based on body surface area 
comparisons and revealed no evidence of impaired fertility or harm to the fetus due to tenofovir. 
There are, however, no adequate and well-controlled studies in pregnant women. Because animal 
reproduction studies are not always predictive of human response, TDF should be used during 
pregnancy only if clearly needed.  Pregnancy is an exclusion criterion for this study.  We will use 
urine pregnancy tests monthly to monitor for pregnancy.  Participants who become pregnant will 
have study drug withdrawn.  We will attempt to monitor participants until the conclusion of the 
pregnancy and the outcome of the pregnancy will be reported to the Gilead Sciences 
Antiretroviral Pregnancy Registry, as described in the package insert for TDF. 
 
Study product interruption 
Treatment with the study product may be interrupted temporarily or permanently for any of the 
following reasons: 
 
·  The participant ran out of supplies for whatever reason (e.g., she missed a visit); in this case 
the date of interruption is the date of her last product use 
·  An adverse event 
·  The Investigator decides to withdraw the study product temporarily in the interests of the 
safety and well being of the participant  
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·  The participant considers it to be in her best interest not to use the study product   
·  Pregnancy  
·  The participant becomes HIV positive 
 
Whenever the study product is interrupted, the information will be noted on the follow-up DCF.  
For all except the first reason listed above, the date of the interruption is the date on which the 
Investigator decides to interrupt the treatment and if possible, follow-up should be continued 
until resolution of the AE. If possible, participants will be tested for HIV so that the status is 
determined at the time of product interruption. 
 
Participants who have had study drug interruption may resume study product use and will be 
given the study product to which they were originally randomized.  At the time of product 
resumption the participant will be tested for HIV so that status is determined.   
3.6.2  Study phases 
 
The screening and recruitment phase will be discontinued when the required number of 
participants has been enrolled.  This is anticipated to take 6 months, but may occur earlier or 
need to be extended. 
 
The scheduled follow-up phase will end 12 months after completion of the recruitment phase.  
The last woman recruited will finish 12 months of follow-up.  Any participant being followed for 
an AE at the end of the scheduled follow-up period will be followed until her AE resolves or the 
Investigator determines it is safe to discontinue follow-up. 
3.6.3  Study 
 
The study will continue until the planned end of the study, or until such time as: 
 
·  FHI decides to discontinue the study.  FHI may discontinue a site/investigator due to 
noncompliance with protocol or regulations 
·  The IRB decides to discontinue the study 
 
If the study is discontinued before the planned end, each participant remaining in the study at 
that point will be seen for a final follow-up visit.  HIV seroconversions detected through this 
follow-up visit will be included in the analysis. 
3.7  Study Product Accountability 
 
The study sites will receive a supply of study products sufficient for the anticipated number of 
study participants.  All supplies must be stored in a limited access area that is securely locked.  
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The study site will also procure male latex condoms to dispense for use with the study product. 
 
For purposes of inventory accountability, the study site will not make supplies of the study 
product available for distribution by any person not part of the study staff or provide these 
supplies to persons not enrolled in the study.   
 
The study site is required to maintain records of the disposition of each unit of study product 
received and dispensed, including dates and quantities of distribution to participants, by 
participant ID number.    All unused supplies of the study product must be returned to FHI at the 
end of the study, or disposed of in a manner specified by FHI. 
3.8  Randomization Codes 
 
The FHI Randomization Manager will maintain the trial treatment randomization codes.  The 
code for an individual participant will be made available to the FHI Study Clinician, should the 
need arise to reveal the code.  It is anticipated that the unmasking will occur rarely and then only 
if knowledge of the treatment group would affect health care for the participant. The Investigator 
will immediately notify the FHI Project Leader if he suspects that unplanned unmasking has 
occurred. 
3.9  Data Directly Recorded on DCFs 
 
All DCFs used in the field for this study will have data that is directly recorded on them and will 
be considered source documents.  Other source documents include, but are not be limited to, staff 
journals, medical notes, screening and enrollment logs, laboratory results, pill dispensing 
records, consent forms, and reimbursement logs. 
4.0  SELECTION OF PARTICIPANTS 
 
The target population is women who are sexually active and at high risk of HIV.  High risk for 
the purposes of this study includes having intercourse, on average, three times per week and 
having had more than three different sexual partners in the last month. 
4.1  Eligibility Criteria 
 
To be eligible for inclusion in this study, a woman must be HIV seronegative and: 
 
·  Be willing and able to give informed consent 
·  Be 18 years to 35 years old, inclusive 
·  Be sexually active (on average, three coitus per week) 
·  Have had more than three sexual partners in the last month 
·  Be willing to use study product as directed  
·  Be willing to adhere to follow-up schedule 
·  Be willing to participate in the study for up to 12 months 
·  Not be pregnant, breast feeding, or desire a pregnancy during the 12 months of participation  
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·  Have adequate renal function (serum creatinine <1.5 mg/dL) 
·  Have adequate liver function (hepatic transaminases (ALT and AST) <3 x ULN 
·  Have adequate serum phosphorus (>2.2 mg/dL) 
·  Be in general good health (no active, serious infections that require parenteral antibiotics, no 
active clinically significant medical conditions, including heart disease, diabetes, asthma, 
alcoholism, and cancer) 
4.2  Loss to Follow-up Procedures 
 
If a participant fails to appear for a scheduled visit, at least three attempts to contact her should 
be made over the subsequent 30 days.  These attempts should be documented in the participant’s 
study file.  After these three attempts, no further efforts need be made to find her, but her file 
should remain open until study closeout. 
 
If the participant does not return to the study before the study is closed, the Final Disposition 
Form will be completed at the time of study closeout.  The form should indicate that the 
participant was lost to follow-up.  The “lost to follow-up” designation cannot be made for any 
participant until the closing date of the study. 
 
Participants will be evaluated for efficacy up until the last follow-up visit. 
5.0  STUDY PRODUCTS AND TREATMENTS 
5.1  Products 
 
Tenofovir DF (GS-4331-05) tablets will be supplied by Gilead Sciences, Inc.  Tenofovir DF 
tablets are almond-shaped film-coated tablets containing 300 mg of TDF. Each tablet contains 
the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, 
pregelatinized starch, croscarmellose sodium, and magnesium stearate. 
 
Placebo tablets to match the tenofovir DF tablets contain inactive ingredients listed above and 
denatonium benzoate to provide a bitter taste to match the active tablets. 
 
TDF or placebo tablets are packaged in white high-density polyethylene (HDPE) bottles with a 
white child-resistant cap. Each bottle contains 30 tablets. Each bottle also contains a single silica 
gel canister to protect the product from humidity and fiber packing to protect the product during 
handling and shipping. TDF or placebo tablets should be stored before dispensing to participants 
at 25°C; excursions permitted to 15-30°C.  Each bottle will be labeled with a randomization 
number, the protocol number, expiration date, and sponsor address. 
 
To ensure product stability, drugs should not be dispensed in a container other than the container 
in which they are supplied. Participants will be instructed to return unused study medication in 
the original container at each study visit. 
 
·  The dose is 300mg (one tablet) once daily with a meal or just afterwards. 
·  The tablets should be swallowed whole.  
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·  TDF works best if there is a constant amount in the bloodstream. It is therefore very 
important to take the tablets regularly. If a dose is forgotten, take it as soon as remembered.  
·  The doses should be taken as close as possible to twenty-four hours apart at the same time 
each day. It is essential that a daily dose is not missed. 
5.2  Concomitant Treatments 
 
Nephrotoxic drugs (group A), drugs that slow kidney excretion of drugs (B), drugs directed at 
immune system modulation (group C), and other retroviral drugs (D) should not be used during 
the study.  The following medications are excluded while patients are participating in the study: 
 
·  A.  Nephrotoxic agents 
o  aminoglycoside antibiotics 
o  IV amphotericin B 
o  cidofovir 
o  cisplatin 
o  foscarnet 
o  IV pentamidine 
o  oral and IV vancomycin 
o  oral or IV ganciclovir 
o  other agents with significant nephrotoxic potential 
·  B.  Drugs that slow kidney excretion 
o  Probenecid 
·  C.  Immune system modulators 
o  Systemic chemotherapeutic agents (i.e., cancer treatment medications) 
o  Systemic corticosteroids 
o  Interleukin-2 (IL-2) 
o  Immunomodulators 
·  D.  Other antiretrovirals 
 
Should participants need to start treatment with any excluded concomitant medication, FHI 
should be informed as soon as possible after initiation of the new medication.  In instances where 
an excluded medication is initiated prior to discussion with FHI, the Investigator must notify the 
FHI as soon as he/she is aware of the use of the excluded medication. 
5.3  Monitoring of Product Compliance 
 
Participants will return the unused tablets and bottle at each month’s follow-up visit.  Unused 
tablets will be counted and recorded on the appropriate DCF.   
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6.0  EFFECTIVENESS AND SAFETY ASSESSMENT 
6.1  Effectiveness Parameters 
 
An incident HIV infection is defined as follows: 
 
·  The presence of HIV antibodies by OraQuick® rapid test and confirmed by an ELISA from 
serum collected by a finger prick at a follow-up visit, and  
·  The absence of HIV antibodies by OraQuick on a sample collected at the previous visit  
6.2  Methods and Timing of Effectiveness Parameters 
 
Oral mucosal transudate (OMT) specimens will be tested for HIV-1/2 antibodies at screening, 
enrollment, and then monthly throughout follow-up using OraQuick.  OraQuick HIV-1/2 is a 
rapid test device that can detect antibodies to the HIV disease within 20 minutes.  OraSure 
Technologies, Inc makes OraQuick.   
 
The OraQuick results will be available 20 minutes after collection.  If the OraQuick test is 
positive, the participant will be told that the test results are preliminary and a finger prick 
specimen will be collected on filter paper and tested by ELISA.  If the OraQuick and ELISA 
results are discordant, a Western blot from the finger prick specimen will be done.  (See section 
14.1 for quality control of the OMT HIV sampling.) 
6.3  Safety Measurements  
 
We will measure serum ALT, AST, creatinine, and phosphorus as safety measures. 
 
The lab tests called "liver function tests" actually measure the levels of enzymes found in the 
liver, heart, and muscles. Enzymes are proteins that cause or increase chemical reactions in 
living organisms. High enzyme levels can indicate liver damage caused by medications, alcohol, 
hepatitis, or recreational drug use. 
·  ALT (alanine aminotransferase), formerly called serum glutamate pyruvate transaminase or 
SGPT)  
·  AST (aspartate aminotransferase), formerly called serum glutamic-oxaloacetic transaminase 
or SGOT)  
AST and ALT are sensitive indicators of liver injury. AST is present in the heart, skeletal 
muscle, brain, and kidney as well as in the liver. AST levels thus rise in myocardial infarct, heart 
failure, muscle injury, central nervous system disease, and other non-hepatic disorders. AST is 
relatively nonspecific, but high levels indicate liver cell injury. AST is reliable for routine 
screening for liver disease. Values > 500 IU/L suggest acute viral or toxic hepatitis and occur 
with marked heart failure and occasionally with common bile duct stones. The magnitude of the 
elevation has no prognostic value and does not correlate with the degree of liver damage. Serial  
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testing provides good monitoring.  A fall to normal indicates recovery unless associated with the 
end stages of massive hepatic necrosis. 
ALT is found primarily in liver cells and thus has greater specificity for liver disease but offers 
little other advantage. In most liver diseases, the AST increase is less than that of ALT 
(AST/ALT ratio < 1), but in alcohol-related liver injury, the ratio frequently is > 2.  
·  Creatinine is a waste product of protein digestion and a measure of kidney function. High 
levels are usually due to kidney problems. Clinicians use the creatinine level as most direct 
sign of how well the kidneys are removing waste products from the body. 
·  Phosphorus, like calcium, is a major component of bones. Low levels of phosphorus for a 
long period of time can cause damage to bones, nerves and muscles. High phosphorus levels 
are most often due to kidney failure. 
6.4  Methods and Timing of Safety Measurements 
 
A blood sample will be drawn from participants for AST, ALT, creatinine, and phosphorus 
testing at screening (-1), and months 1, 3, 6, 9, and 12 during follow-up.   
7.0  ADVERSE EVENTS AND REPORTING REQUIREMENTS 
7.1  Adverse Events 
 
Study participants will be provided with contact information and instructions to contact the 
Investigator or designee to report any adverse events (AEs) they may experience, except for life-
threatening events, for which they will be instructed to seek immediate emergency care.  Based 
on the results of the Investigators’ assessment, s/he will recommend either continuation or 
discontinuation of product use.  The Investigator also may prescribe or recommend the use of 
medications or other preparations to treat the AE. 
 
Where feasible and medically appropriate, participants will be encouraged to seek medical care 
where the site study clinician is based, and to request that the clinician be contacted upon their 
arrival.  With appropriate permission of the participant, records from all non-study medical 
providers related to AEs will be obtained and required data elements will be recorded on study 
case report forms.  All participants reporting an AE will be followed clinically, until the AE 
resolves (returns to baseline) or stabilizes. 
 
Study site staff will document on study DCFs all AEs reported by or observed in enrolled study 
participants regardless of severity and presumed relationship to study product.  Site staff also 
will report information on all AEs to their IRB in accordance with US Federal regulations and 
local IRB requirements. 
 
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with 
the use of a medicinal product, whether or not considered related to the medicinal product.  Pre-
existing events, which increase in frequency or severity or change in nature during or because of 
use of a drug in human clinical trials, will also be considered as adverse events.  AEs may also  
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include pre- or post-treatment complications that occur as a result of protocol-mandated 
procedures (e.g., invasive procedures such as biopsies). 
 
Any medical condition or clinically significant laboratory abnormality with an onset date before 
the first date of study drug administration is considered to be pre-existing, and should be 
documented on the DCF noting that it is pre-existing.  
 
Any AE (i.e., a new event or an exacerbation of a pre-existing condition) with an onset date after 
study product administration up to the last day on study (including the follow-up) should be 
recorded as an AE on the appropriate DCF. 
  
The Investigator must determine the severity of the AE and document it on the appropriate DCF 
(AE Form). Each adverse event that the participant is aware of should be graded for severity 
using the following scale: 
 
·  Very slight: participant was aware of the adverse event and it disappeared soon after or it 
was on and off. 
·  Mild: participant was aware of the adverse event all of the time, but was still able to do all 
activities. 
·  Moderate: the participant had to discontinue some activities due to the adverse event. 
·  Severe: the participant was incapacitated by the adverse event and unable to perform normal 
activities.  
 
An AE does not include: 
 
·  Medical or surgical procedures (e.g. surgery, endoscopy, tooth extraction, transfusion); the 
condition that leads to the procedure is an adverse event. 
·  Pre-existing diseases or conditions present or detected prior to start of study drug 
administration that do not worsen. 
·  Situations where an untoward medical occurrence has not occurred (e.g. hospitalization for 
elective surgery, social and/or convenience admissions). 
·  Overdose of either study drug or concomitant medication without any signs or symptoms 
unless the participant is hospitalized for observation. 
7.2  Relationship of adverse event to study product 
 
The Investigator must determine the relationship of the AE to the product under investigation 
and document on the appropriate DCF (AE Form). For each AE, an assessment of the relatedness 
to the test agent should be made using the following scale:  
 
·  Unrelated: Onset of the AE had no reasonable temporal relationship to administration of the 
study product or a causal relationship to administration of the study product is biologically 
implausible or the event is attributed to an alternative etiology.  
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·  Possibly Related: Onset of the AE has a reasonable temporal relationship to study product 
administration and a causal relationship is not biologically implausible. 
·  Probably Related: Onset of the AE has a strong temporal relationship to administration of 
the study product that cannot be explained by the participant’s clinical state or other factors 
and a causal relationship is not biologically implausible. 
·  Definitely Related: Onset of the AE shows a distinct temporal relationship to administration 
of the study product that cannot be explained by the participant’s clinical state or other 
factors or the AE occurs on re-challenge or the AE is a known reaction to the product or 
chemical group or can be predicted by the product’s pharmacology. 
 
These criteria in addition to good clinical judgment should be used as a guide for determining the 
causal assessment.  If it is felt that the event is not related to study drug therapy, then an 
alternative explanation should be provided. 
7.3  Reporting adverse events 
 
All AEs occurring during the study will be reported on the appropriate DCF (AE Form). The 
Investigator must provide on this form information on symptoms, time of onset, severity, 
frequency, product-relatedness, action(s) taken, and participant outcome.   FHI’s Study Clinician 
may request additional information from the site if additional information is needed to evaluate 
the AE. 
7.4  Serious Adverse Events 
 
A serious adverse event (SAE) for a drug or biologic product or medical procedure is defined as 
any experience that suggests a significant hazard, contraindication, side effect, or precaution. A 
serious adverse event includes any adverse experience that results in any of the following 
outcomes: 
 
·  Death  
·  A life-threatening adverse drug experience  
·  Inpatient hospitalization or prolongation of existing hospitalization  
·  A persistent or significant disability/incapacity 
·  A congenital anomaly/birth, or 
·  An important medical event that, based on medical judgment, may jeopardize the patient or 
subject and may require intervention to prevent one of the outcomes listed above.  
 
Examples of such events are: 
 
·  Intensive treatment in an emergency room or at home for allergic bronchospasm 
·  Blood dyscrasias or convulsions that do not result in hospitalization 
·  Development of drug dependency or drug abuse. 
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Clarification of SAEs: 
·  Death is an outcome of an adverse event, and not an adverse event in itself. 
·  All deaths, regardless of cause, must be reported for participants on study and for deaths 
occurring within 30 days of last study product use or within 30 days of last study evaluation, 
whichever is longer. 
·  “Occurring at any dose” does not imply that the participant is using study product at the time 
of the event.  Product use may have been interrupted temporarily prior to the onset of the 
SAE, but may have contributed to the event. 
·  “Life-threatening” means that the participant was at immediate risk of death from the event 
as it occurred.  This does not include an event that might have led to death, if it had occurred 
with greater severity. 
·  Complications that occur during hospitalizations are AEs.  If a complication prolongs 
hospitalization, it is a SAE. 
·  “Inpatient hospitalization” means the participant has been formally admitted to a hospital for 
medical reasons, for any length of time.  This may or may not be overnight. It does not 
include presentation and care within an emergency department unless the participant is 
“admitted”. 
·  The Investigator should attempt to establish a diagnosis of the event based on signs, 
symptoms and/or other clinical information.  In such cases, the diagnosis should be 
documented as the AE and/or SAE and not the individual signs/symptoms. 
7.5  Reporting Serious Adverse Events 
 
All serious adverse events must be reported to FHI within 24 hours of the study site becoming 
aware of the problem.  The Investigator should complete a FHI SAE Report Form and fax it 
simultaneously to: 
 
·  Dr. Kavita Nanda (the FHI Study Clinician) 
·  Mr. David Borasky (The FHI protection of Human Subjects Committee Representative) 
 
Family Health International 
Telephone:  919-544-7040 
Fax:  919-544-7261 
Email: dborasky@fhi.org and knanda@fhi.org 
 
In cases in which a SAE Report Form cannot be faxed within 24 hours, the Investigator may 
report the SAE via telephone or e-mail; however, a SAE Report Form must be completed as soon 
as possible after the informal report.  Based on the preliminary information, the FHI Study 
Clinician will complete an interim SAE Report Form and forward it to the PHSC Representative 
for processing.  The Study Clinician will make sure to update this information as soon as he/she 
receives a complete SAE Report Form from the Investigator.  
 
The FHI Study Clinician and FHI Chief Medical Officer will complete the FHI SAE Review 
Form within 5 days of receipt of the SAE Report Form (including interim Report Form) from the 
site.  
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If the SAE is unexpected, and related to the use of an investigational product, the FHI Study 
Clinician will alert the FHI Regulatory Associate immediately of receipt of the SAE Report 
Form that an SAE has occurred that may be reportable to the regulatory agency. The FHI Study 
Clinician will process and report all SAEs to the Regulatory Associate and PHSC.  
 
The Investigator will be responsible for proper reporting of all SAEs to the local IRB, to the FHI 
Study Clinician and PHSC Representative as specified in the protocol. 
7.6  Adverse Event Management 
 
See Appendices 1, 2, and 3 for more details. 
7.6.1  Grades 1 and 2 laboratory abnormality or clinical event (except serum creatinine 
elevation) 
 
·  Continue study drug at the discretion of the Investigator.  
 
(See Appendix 2 for details) 
7.6.2  Grade 3 laboratory abnormality or clinical event (except serum creatinine elevation) 
 
·  For a Grade 3 laboratory abnormality or clinical event, study drug may be continued if the 
event is considered to be unrelated to study drugs. 
·  For a Grade 3 clinical event, or laboratory abnormality confirmed by repeat testing, that is 
considered to be related (any degree of relatedness) to study drugs, study drugs should be 
withheld until the toxicity returns to at least Grade 2, at which point the patient can be re-
challenged with study drug. 
·  If toxicity recurs to Grade 3 following re-challenge with study drugs and is considered 
related to the study drug, then the study drug should be permanently discontinued and 
patients managed according to local practice. 
·  Recurrence of events considered unrelated to study drug do not require permanent 
discontinuation of the study drug. 
 
(See Appendix 2 for details) 
7.6.3  Grade 4 laboratory abnormality or clinical event (except serum creatinine elevation) 
 
·  For a Grade 4 clinical event, or laboratory abnormality confirmed by repeat testing, that is 
considered related to any of the study drugs, all study drugs should be permanently 
discontinued and patients managed according to local practice. The patient should be 
followed as clinically indicated until the event resolves to baseline, or is otherwise explained, 
whichever occurs first.  
 
·  For a Grade 4 laboratory toxicity that is not confirmed by repeat testing should be managed 
per algorithm for the new toxicity grade.  
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·  Study drug may be continued without dose interruption for a Grade 4 laboratory abnormality 
or clinical event considered unrelated to the study drug. 
 
(See Appendix 2 for details) 
7.6.4  Grade 1 serum creatinine elevation 
 
For the purposes of serum creatinine, the baseline value is defined as the last value prior to the 
administration of the first dose of study drugs. This value must be obtained from the laboratory. 
Serum creatinine values = 0.5 mg/dL above baseline should be confirmed by repeat testing 
within 3 calendar days of receipt of results and before study drugs discontinuation, unless such a 
delay is not consistent with good medical practice. 
 
·  For Grade 1 serum creatinine elevations, patients may continue study drug, but it is 
recommended that participants be monitored weekly until the serum creatinine returns to the 
original baseline value or <0.3 mg/dL from baseline. 
 
(See Appendix 3 for details) 
7.6.5  Grades 2-4 serum creatinine elevations 
 
·  Study drug should be permanently discontinued in the event that repeat testing of serum 
creatinine confirms a value equal to or higher than 2.1 mg/dL. The patient should be 
followed at periodic intervals not less than weekly, until the serum creatinine falls to within 
0.3 mg/dL of the baseline value. 
 
(See Appendix 3 for details) 
7.7  Social Risk Events 
 
No social risk events are expected from participation in this study.  However, if the Investigator 
learns of a social risk event, he will report the event on the Social Risk Event Form. 
8.0 STUDY VISIT SUMMARY  
 
The participants will make visits to study sites for one screening, one enrollment, and 12 
monthly follow-up visits.  A table summarizing study procedures is available in Appendix 4.   
8.1  Screening Visit  
 
The study, including potential risks and benefits of participation, will be explained to prospective 
participants during the screening visit and before any procedures are begun.  This will include a 
review of the study purpose and procedures.   Each woman will be asked to sign (or provide 
other mark) a consent form for the screening procedures, and will be given a signed copy of the 
consent form to take home. 
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All volunteers will be assigned an ID number (for the purpose of tracking their lab tests), and 
evaluated to determine their eligibility according to the participation eligibility criteria. 
 
The following will be done: 
 
·  An interview with the woman to make sure she understands the study schedule and is willing 
to comply with study requirements  
·  Screening consent obtained 
·  Screening questionnaire 
·  A urine pregnancy test 
·  Pre-test and post-test HIV counseling  
·  OMT sample for HIV testing and a finger prick specimen if needed for confirmation 
·  Blood drawn for kidney and liver functions 
·  The women will be asked to return in 4 weeks for the enrollment visit, when they will receive 
the results of the blood tests.   
·  All women will be instructed in proper condom use. 
8.2  Enrollment Visit 
 
If the woman meets all eligibility criteria, she will receive a detailed explanation of study 
procedures, and counseled in the importance of returning for follow-up.  If the screening test for 
HIV was negative, the potential participant will be re-screened with OraQuick® on the day of 
enrollment.  She will be asked to sign an enrollment consent form, and will be given a signed 
copy to take home.  She will then be randomized. 
 
The following will be done at the enrollment visit: 
 
·  An interview with the woman to make sure she understands the study schedule and is willing 
to comply with study requirements  
·  Enrollment consent obtained 
·  Enrollment questionnaire 
·  A urine pregnancy test 
·  Pre-test and post-test HIV counseling  
·  OMT sample for HIV testing and finger prick specimen if needed for confirmation 
·  Randomization 
·  Drug and condom distribution 
 
Counseling 
The counselor will review study product use, and methods of HIV/STI transmission and 
prevention.  The use of condoms with all partners, including primary sexual contacts, will be 
emphasized.  Staff will also stress that this is a controlled trial of a product of unknown 
effectiveness in the prevention of HIV transmission and that condoms should be used for all 
sexual contacts with all partners.  This information will be repeated at each follow-up counseling 
session. 
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Study Product 
Each participant will receive a supply of TDF or placebo and offered condoms.  Participants will 
receive supplies of condoms in quantities anticipated to last until the next visit.  A participant can 
return between scheduled visits to obtain more condoms if needed.  A product-dispensing log 
will be maintained by the clinic and field staff to track all product distribution.   
 
Pelvic examination 
The pelvic examination will only be done if the participant has symptoms or a problem that 
needs to be investigated.  If a wet mount is positive for T. vaginalis, yeast or bacterial vaginosis, 
the woman can be enrolled while starting treatment.  Any other diagnosed curable STD can be 
treated and the woman enrolled.  STD treatment will be recorded on the appropriate DCF.   
8.3  Follow-up Visits  
 
Each participant will have a follow-up visit at a study site convenient for her and at the study 
clinic (months 1, 3, 6, 9, and 12).  Study sites distributed throughout the study cities will be 
chosen as follow-up sites.  Each outreach worker will be assigned to a study site and will use the 
site as a base of operation.  The outreach worker is responsible for monthly counseling, 
interviewing, re-supplying the participants with products, and, if necessary, home visits to ensure 
that each participant completes the study.  Activities at the monthly visit include: 
 
·  A questionnaire will be administered to collect information on use of product and condoms 
·  Participants will be counseled about product and condom use 
·  Participants will be re-supplied with study product and offered condoms in an amount 
sufficient to last until the next follow-up visit 
·  A pregnancy test 
·  Participants will provide an OMT specimen for HIV testing and a finger prick specimen if 
needed for confirmation 
 
Study participants will be met at the clinic by the outreach worker for visits at months 1, 3, 6, 9, 
and 12 so that venous blood can be taken for the safety parameters. 
 
If at any visit, the staff person or the study participant thinks that an examination is necessary, 
the participant will be referred to the study clinic for an examination. 
8.4  Interim Contacts and Unscheduled Visits 
 
Participants may make interim contacts and unscheduled visits at the participant’s request or as 
deemed necessary by the Investigator at any time during the study.  All interim contacts and 
unscheduled visits will be documented in the participants’ study records and on applicable DCF. 
 
When an interim contact or unscheduled visit occurs in response to AEs experienced by study 
participants, study staff will assess the reported event clinically and provide or refer the 
participant to appropriate medical care.  
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Study participants will be instructed to contact their study clinic in the event of any adverse 
events (AE) except for life-threatening AE, for which participants will be instructed to seek 
immediate emergency care.  The AE will be reported on the appropriate DCF. 
 
Interim visits are distinguished from adverse event visits in that no health related reaction, effect, 
or abnormality is reported.  Some examples of reasons for an interim visit are: 
 
·  To get more product or condoms 
·  To ask questions of study staff 
·  To discuss problems with study compliance 
·  Interim examination - examination requested but no complaints or symptom  
9.0  STATISTICAL SUMMARY  
9.1  Study Size Justification  
9.1.1  Effectiveness outcome 
 
This study is designed to have 90% power to conclude with 95% confidence that TDF reduces 
the rate of HIV infection by 50% (i.e., power to obtain a one-sided 95% upper confidence limit 
for the rate ratio that is less than 0.5) if the true rate of reduction due to TDF is at least 83%.  
Recruiting 1,200 participants, and following each for 12 months, should provide the required 
number of incident HIV infections (30), assuming that HIV incidence in the placebo group is no 
less than 5/100 person-years, and follow-up is at least 80% at 12 months. 
9.1.2  Safety outcomes 
 
We will assess safety outcomes by treatment group (pooled across sites), as well as in each site-
by-treatment group cohort.  Site-level information will be assessed to provide each country’s 
public health sector with data to make informed safety decisions in their own populations.  As 
demonstrated in Table 1, precise estimates of 12-month event probabilities should be obtained at 
the site-level using the chosen study size.  Furthermore, the study size is adequate to observe 
toxicity outcomes that occur at a modest rate of 5%; the probability that five or more such events 
are observed among a cohort of 200 participants is greater than 95%. 
 
Table 1: 95% Confidence intervals corresponding to 12-month safety event probability estimates, 
assuming 20% loss to follow-up. 
 
Then the 95% confidence interval is…  If estimated 12-month cumulative 
probability is equal to…  Site-level (N=200)  Pooled (N=600) 
1%  (>.000, .024)  (.002, .018) 
2%  (>.000, .040)  (.008, .032) 
3%  (.005, .055)  (.016, .044) 
5%  (.018, .082)  (.032, .068) 
10%  (.056, .144)  (.075, .125)  
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9.2  Analysis Plan Summary 
 
A detailed analysis plan that covers both the final analysis and the planned interim analyses will 
be developed and approved prior to initiation of the study.  The following is a summary of the 
planned analyses.  Any deviations to be made from this summary plan will be documented in the 
detailed analysis plan. 
 
All primary and most secondary analyses will be conducted on an intent-to-treat basis.  However, 
in order to assess the effectiveness and safety of TDF among those participants who complied 
with key aspects of the study protocol and to evaluate the potential impact of treatment on loss to 
follow-up, various additional analysis populations may be defined in the detailed analysis plan.  
Any key decisions regarding the timing of outcomes, the appropriateness of test statistics or 
model assumptions, or any other statistical issues will be made in a masked review of the data 
(i.e., masked to the true treatment assignments).  Unmasking with respect treatment assignment 
will only be done for the final interpretation of the results, unless otherwise required by the data 
monitoring committee (DMC) (see section 10.3). 
9.2.1  Analysis of effectiveness outcomes 
 
All primary analyses will be conducted on an intent-to-treat basis.  Incidence rates of HIV 
infection in the two treatment groups will be calculated, and the effect of TDF on the incidence 
of infection will be determined by calculating an upper 95% confidence bound for the rate ratio 
(TDF versus placebo).  This upper confidence bound will be compared to 0.5 to test the 
hypothesis that the reduction in the HIV infection rate due to TDF is at least 50% (i.e., a one-
sided test of superiority with a = 0.05).  The estimated rate ratio and 95% confidence bound will 
be obtained using Cox proportional hazards regression, controlling for site, if the model 
assumptions are found to be appropriate.  Otherwise, crude incidence ratio estimates and 
confidence bounds will be obtained based on the ratio of the numbers of new cases to the total 
lengths of treatment exposure.
6  Time to HIV infection, in days, will be computed as the 
difference between the date of HIV infection, estimated using the midpoint of the study interval 
in which the first positive HIV test was obtained (see Section 6.1) and the enrollment date, plus 
one.  Potential prognostic factors identified prior to study initiation will be adjusted for in 
supporting analyses of incident infections.  Likewise, supporting analyses will evaluate the 
treatment effect across sites by introducing treatment-by-site interaction terms to the proportional 
hazards regression model. 
9.2.2  Safety outcomes 
 
Primary laboratory safety endpoints include serum creatinine and phosphorus for kidney 
function, and AST and ALT for hepatic function.  Here, laboratory safety events for creatinine 
are defined as the occurrence of grade 2-4 serum elevations at any time during follow-up.  
Laboratory safety events for phosphorus, AST, and ALT are defined as the occurrence of grade 
3-4 laboratory abnormalities during follow-up.  Twelve-month cumulative event probabilities for 
each of these endpoints will be estimated based on the time to the first event using the Kaplan-
Meier method and Greenwood’s formula for standard errors.
7  Differences in the estimated 12-
month event probabilities between treatment groups will be presented along with 95%  
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confidence intervals.  In addition, changes in lab results between baseline and follow-up visits 
will be summarized descriptively (e.g., tabulating means, medians, standard deviations, ranges, 
and number of participants with abnormal values), by treatment group and site. 
 
The frequency and percentage of adverse events will by tabulated by body system.  Listings of 
all AE’s will include information on duration, outcome, severity, and relation to product use.  
Differences between treatment groups in the frequency of body-system level AE’s will be 
evaluated using exact, two-sided 0.05 level tests, and approximate 95% CIs stratified by site. 
9.3  Interim Analysis Plan Summary 
 
FHI will conduct interim analyses of safety data at 6 and 12 months after enrollment begins (see 
section 10.3).  Each interim analysis will include comparability of masked treatment groups at 
enrollment, compliance with intervention, discontinuation rates, and intervention-associated 
morbidity.   
 
In addition to providing safety data summaries, a biostatistician not otherwise associated with the 
study will perform an interim study size re-assessment calculation prior to the first interim safety 
analysis.  S/he will make recommendations to the DMC regarding the potential need to increase 
study size if HIV infection or follow-up rates are lower than anticipated (a reduction in the total 
study size on grounds of excess power will not be permitted).  Any such recommendations will 
be based on the infection rate pooled across both treatment groups, and not on observed 
differences between treatment groups; hence, no type I error rate adjustment will be required 
when evaluating the primary hypothesis test specified in section 9.2.1. 
10.0  MONITORING PLAN SUMMARIES 
10.1  Clinical Monitoring Plan 
 
Site visits by the FHI clinical monitors will be made in accordance with FHI policy and SOPs.  
The purpose of the monitoring is to assure the quality and accuracy of data collected on the DCF 
and entered in the database, and to determine that all regulatory requirements surrounding 
clinical trials are met. 
 
The Investigator will allow the clinical monitors, the regulatory agencies, and FHI designated 
persons to inspect study documents (e.g., consent forms, drug distribution forms, DCF) and 
pertinent clinic records for confirmation of the study data. 
 
Various authorized individuals may visit the study site to audit the progress of this study (e.g., 
FHI personnel, product manufacturer personnel, regulatory personnel).  A site visit log will be 
maintained at the study site in which all site visits made by authorized individuals are recorded.  
All clinical records and the DCF for the participants enrolled in this study will be made available 
for review by these authorized individuals. 
 
Before the study begins, the clinical monitors will conduct an evaluation visit at each site to 
determine the suitability of the site for the research study.  In addition, there will be a study  
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initiation visit (study start-up), quarterly monitoring visits (to track study progress) and a close-
out visit.  The overall responsibility of the monitors is to ensure that the study is being conducted 
according to the protocol, FHI SOPs, ICH/GCP and applicable regulatory requirements. 
 
A detailed monitoring plan will be developed for this study and will be used by all clinical 
monitors.  This plan will specify the responsibilities and qualifications of the identified clinical 
monitors, back-up provisions, in-house monitoring procedures, and site monitoring visit 
procedures.  All monitoring visits will be documented. 
10.2  Safety Monitoring Plan 
 
The Study Clinician will review all abnormal safety parameter AEs (creatinine, phosphorus, 
ALT, or AST).  The Study Clinician will review quarterly a cumulative summary of the AEs 
reported.  The Study Clinician will review (in compliance with FHI SOP) all SAEs. 
10.3  Data Monitoring Committee 
 
A Data Monitoring Committee (DMC) will review the safety profile of this study while the study 
is ongoing.  The committee will convene 6 and 12 months after start of enrollment.  The DMC 
will examine the safety results of the trial.  The results broken out by the treatment groups will 
remain masked for the FHI personnel. 
No formal stopping rules will be used by the DMC for safety outcomes.  Rather, a clinical 
assessment will be made to determine if the nature, frequency, and severity of adverse effects 
associated with TDF warrant the early termination of the study in the best interests of the 
participants. 
FHI has no a priori intent to consider early termination of the study based on effectiveness so 
that the extended safety data can be collected.  Data on safe use in non-HIV infected people for 
at least one year is as important as the HIV outcome. 
11.0  DATA MANAGEMENT PLAN SUMMARY  
 
A detailed data management plan will be written prior to study initiation.  It will be modified if 
significant changes are required, in order to document how data were handled in the study.  The 
following is a brief summary of the plan.  
 
Study sites will capture clinical data on paper DCFs.  After each patient visit, sites will enter data 
directly from the source documents into the eDCF using InForm software.  Once the data have 
been entered and submitted, the information is encrypted and transmitted over the Internet to a 
PharmaLinkFHI database server. The server runs the pre-programmed validation checks against 
the new data and immediately returns any automated queries to the site.  An audit trail of each 
change to the data is captured within the system.  
Protocol, Study 9780    Approved by PHSC 
Version 1.0  32 of 51  Last Revised August 22, 2003 
 
FHI clinical monitors will perform the in-house clinical review of the participant data remotely 
for clinical consistency, outliers, AEs, and other abnormalities.  Based on this review, manual 
queries are entered into InForm and are immediately available to sites for reply.  All queries are 
automatically tracked in the database for auditing purposes using a full audit trail.   
 
Throughout the study, the PharmaLinkFHI data manager will review the data on an aggregate 
level to identify potential areas requiring further clarification and look for data quality trends.  
This review supplements the remote page-by-page eDCF review carried out by the FHI monitor, 
and allow PharmaLinkFHI to identify potential data inconsistencies that only appear when one 
value is compared to the other values that have been collected during the study.  Regular 
aggregate data review will allows PharmaLinkFHI to substantially decrease the time to providing 
the data set for analysis by proactively addressing many data issues that usually only appear at 
the end of a study when the summary data displays are reviewed. 
 
PharmaLinkFHI will perform adverse event coding using MedDRA, which is a standard 
dictionary and concomitant medication using WHO.  FHI will review and approve all coding 
prior to final data base closure.   
12.0  PROTOCOL VIOLATIONS 
 
Emergency departures from protocol that eliminate an apparent immediate hazard to participants 
and are deemed crucial for the safety and well being of that participant may be instituted for that 
participant only – the Investigator will contact FHI as soon as possible.  The Investigator will 
notify the IRB and FHI Project Leader in writing as soon as possible and document on the DCF 
reasons for deviation and ensuing events. 
12.1  Protocol Violations 
 
·  Omission or inadequate administration of informed consent  
·  Inclusion/exclusion errors, including legal age limit 
·  Treatment errors:  no treatment or incorrect treatment (including dose or regimen, expired 
product), participant compliance problems 
·  Missing or incorrectly timed study procedures and assessments 
·  Forcing a participant to enter or remain in the study 
·  Participants who should have been discontinued from the study due to protocol criteria, but 
were not 
13.0  STUDY DOCUMENTS 
13.1  Study Initiation 
 
The following documents will be in place and monitored by a Clinical Monitor at the study site 
before any potential participants are contacted. 
 
·  Investigator’s Brochure  
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·  FDA Form 1572 
·  Signed protocol and amendments 
·  Sample DCFs 
·  Financial disclosure forms for Investigator and Sub-Investigator 
·  Information given to participants 
o  Consent forms 
o  Other written information 
o  Advertisements 
·  Financial records 
·  Signed agreements between involved parties 
·  IRB approval 
·  IRB composition 
·  Regulatory authority approval 
·  CV for Investigator, Sub-Investigator, and Site Coordinator 
·  Laboratory test normal values 
·  Lab accreditation and lab supervisor’s CV 
·  Instructions for handling of investigational product and trial related materials 
·  Shipping records 
·  Decoding procedures for masked trials 
·  Site Visit Log 
13.2  Study Conduct 
 
During the study the following documents will be in place and periodically monitored by a 
Clinical Monitor at the study site.  Revision of documents will be made if relevant. 
 
·  Revisions to the Investigator’s Brochure 
·  Revisions to the FDA form 1572 
·  Revision to the Financial Disclosure forms 
·  Revision to the protocol and amendments 
·  Revisions to the DCFs 
·  Revisions of information given to participants 
o  Consent forms 
o  Other written information 
o  Advertisements 
·  IRB approvals 
·  IRB composition changes 
·  Regulatory authority approvals 
·  CV for Investigator, Sub-Investigator, and Site Coordinator 
·  Updates of laboratory test normal values 
·  Documentation of investigational product and trial related materials shipment 
·  Relevant communications other than site visits 
·  Signed consent forms 
·  Source documents  
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·  Copies of completed DCFs 
·  Copies of documentation of DCF corrections 
·  Notification of Investigator to FHI of SAEs 
·  Notification of Investigator to local IRB and Regulatory Authorities 
·  Notification by FHI or Sponsor to Investigator of safety information 
·  Interim or annual reports to IRB, Regulatory Authorities, and FHI 
·  Participant screening log 
·  Participant ID code list 
·  Participant enrollment log 
·  Investigational products accountability documents 
·  Staff signature list 
·  Site Visit Log 
·  Progress Reports to FHI 
13.3  Study Completion 
 
After completion of the study, all of the documents in 13.1 and 13.2 should be in the file together 
with the following.   
 
·  Investigational products accountability documents 
·  Documentation of products destruction (if destroyed at site) 
·  Complete participant ID code list 
·  Final report by Investigator to IRB, Regulatory Authorities, and FHI 
13.4  Site Record Retention and Access to Documents at the Site 
 
The signed original informed consent documents for each participant, pink copies of DCFs, and 
originals of all study documentation (e.g. drug inventory forms, participant clinic records, 
original laboratory reports, staff journals, etc.) will be retained by the Investigator.  No records 
may be destroyed without written permission from FHI. 
 
The investigator may be subject to a field audit by FHI to validate the participation of study 
participants and to verify the data reported on the DCFs.  This audit could occur while the study 
is in progress or several years after the study is completed.  All of the participants’ records and 
other study documentation must be filed and accessible on short notice (3-5 days) during the 
study and subsequent retention period. 
14.0  QUALITY CONTROL AND QUALITY ASSURANCE 
14.1  Quality Control of the OMT Sampling 
 
Each time that a scheduled blood specimen is drawn from the participants for the safety 
parameters, an OraQuick HIV test will be performed on the serum.  OraQuick can be conducted 
using whole blood or serum as well as OMT.  We will compare the results of the blood specimen  
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with the OMT specimen at screening, 1, 3, 6, 9, and 12 months during follow-up.  Discrepancies 
will be addressed by testing with ELISA and if discordant, Western blot. 
14.2  Quality Assurance 
 
A Quality Assurance Associate from FHI will conduct a site visit and evaluation after at least 5 
months of study conduct and then again about 6 months before the projected end of the study.  
The QA Associate will evaluate study systems for quality control, monitoring of the study, 
documentation of the study, and overall control of the study. 
15.0  ETHICS AND RESEARCH INTEGRITY 
15.1  Institutional Review Board Review and Approval 
 
Before contact with potential participants, the study must be approved in writing by the 
Institutional Review Board at the site and FHI’s Protection of Human Subjects Committee in 
accordance with FDA regulations (21 CFR Part 56).  The study will be conducted in accordance 
with all conditions of approval by the IRBs.  The sites will obtain written reapproval of the 
research by the IRBs at least annually and forward a copy of the review to FHI. 
15.2  Informed Consent 
 
No participant may be admitted into this study until the Investigator has obtained her legally 
effective informed consent.  An Investigator shall seek such consent only under circumstances 
that provide the prospective participant with sufficient opportunity to consider whether or not to 
participate in the study.  Informed consent must be obtained without coercion, undue influence, 
or misrepresentation of the potential benefits or risks that might be associated with participation 
in the study. 
 
Informed consent encompasses all oral or written information given to the participant about the 
study and the study materials.  This includes the consent form signed by the participant, 
recruitment advertising, and any other information provided to the participant.  All such 
information that is given to the participant will be in a language that is understandable to her.  
The information will not include any language in which the participant is made to waive any of 
her rights or which releases or appears to release the Investigator, the Investigator’s institution, 
or FHI from liability for negligence. 
 
Informed consent will be documented by the use of a written consent form that is signed by the 
participant (or the participant’s mark if she cannot sign).  A copy of the signed consent form will 
be given to each participant. The original signed consent form for each participant will be kept in 
the participant’s study files separate from the DCFs.  The consent form must include each of the 
basic and additional elements of informed consent described in 21 CFR Part 50.25 and must 
describe each of the risks or discomforts to the participant that have been identified by FHI as 
reasonably foreseeable.  
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15.3  Participant Confidentiality 
 
The confidentiality of all participants enrolled into this study will be protected to the fullest 
extent possible.  FHI staff, FDA personnel, or other individuals authorized in writing by FHI 
may audit participant’s clinic records.  However, study participants should not be identified by 
name on any DCF or on any other documentation sent to FHI and will not be reported by name 
in any report or publication resulting from data collected in this study. 
15.4  Research Integrity 
Concern in the United States about the quality of biomedical and behavioral research has led to 
the establishment of regulations and guidelines for handling the allegations of scientific 
misconduct.  As a recipient of U.S. government funding, FHI is required to develop policies and 
procedures related to scientific misconduct that conform to these regulations.  The regulations 
define "misconduct" in science as a "fabrication, falsification, plagiarism, or other practices that 
seriously deviate from those that are commonly accepted within the scientific community for 
proposing, conducting, or reporting research.  It does not include honest errors or honest 
differences in interpretations or judgments of data" (42 CFR 50.102.) 
FHI has specific obligations under these regulations with respect to the handling of information 
related to scientific misconduct that may come to its attention.  In addition, the regulations 
require that FHI establish procedures related to initiating an inquiry, pursuing an investigation, 
and informing a specified circle of authorities should the situation warrant it.  FHI will pursue all 
allegations of misconduct in research or questionable academic conduct that may raise legitimate 
suspicions of misconduct, and will conduct inquiries and investigations to resolve questions 
regarding the integrity of research.  In conducting inquiries during an investigation, FHI will 
focus on the substance of the issue and will be vigilant not to permit personal conflicts between 
colleagues to obscure the facts. 
16.0  PUBLICATION POLICY 
 
All information concerning the drug supplied by FHI to the Investigator and not previously 
published is considered confidential. 
 
The initial publication from this study will be the aggregate multicenter results focusing on the 
primary endpoints of TDF safety and HIV prevention effectiveness.   Subsequent secondary 
analyses and manuscripts, including any single center data, will be agreed upon by members of 
the protocol team and reviewed by FHI.  All suggestions for the manuscript will be returned to 
the first author by FHI within 15 working days of receiving it. 
 
For publication of the main findings of this study, one person from each site, the Project Leader 
and Lead Statistician from FHI will be considered as an author (a total of 5 persons).  Other key 
contributors to the research will be acknowledged as part of the TDF Phase 2 Research Team.  
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17.0  ADDITIONAL INVESTIGATOR RESPONSIBILITIES 
 
In addition to the previously described responsibilities, the Investigator is responsible for signing 
and dating the cover page of this study protocol.  The signed and dated original must be 
submitted to FHI before protocol implementation, and the Investigator at the site must maintain a 
copy with the study files. 
 
All protocol amendments must be signed and dated by the Investigator.  The signed and dated 
original must be submitted to FHI before implementation of the amendment, and the Investigator 
at the site must maintain a copy.  Amendments must be approved by FHI and the IRB before 
implementation. 
 
The Investigator will provide FHI with a curriculum vitae (CV) for himself showing the 
education, training, and experience that qualifies him as an expert in the area of clinical 
investigation specific to the product under investigation and his affiliation with the site at which 
the study is being conducted.  CVs also must be provided for all individuals listed as Sub-
Investigators on the Form FDA-1572 and the Site Coordinator showing the education, training, 
and experience that qualifies them for their role in the study, and their affiliation with the study 
site.  If and when any personnel listed on the 1572 changes, the Investigator will notify FHI and 
provide a CV for any new staff on the form. 
 
The Investigator will supply FHI with copies of the current license and/or laboratory certification 
(such as the Clinical Laboratory Improvement Act [CLIA] certification) of any laboratory used 
for the study.  The Investigator is responsible for obtaining any updates to these documents and 
sending them to FHI in a timely fashion.  This includes documentation of the normal ranges of 
the laboratory tests used by the laboratory.  The Investigator will ensure that appropriate health 
care or referral is provided for the study participants throughout the study.  Copies of all these 
documents must be maintained at the site. 
 
Throughout the course of the study, the Investigator will prepare and submit to FHI whatever 
reports are required and detailed in the Subcontract Agreement to be signed prior to initiating the 
study.  These reports summarize the accomplishments of the assignment and usually include the 
following: 
 
·  all changes in the research activity; and 
·  all unanticipated problems involving risks to participants or others. 
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APPENDIX 1: COMMON TOXICITY GRADING SCALE 
GILEAD SCIENCES modified from NIAID 
 
 
 
 
Hematology  Grade 1  Grade 2  Grade 3  Grade 4 
Hemoglobin  8.0-9.4 g/dL  7.0-7.9 g/dL  6.0-6.9 g/dL  < 6.0 g/dL 
Absolute Neutrophil 
Count  1000-1500/mm
3  750-999/mm 
3  500-749/mm 
3  ￿￿￿￿￿￿￿￿￿￿
Platelets  75,000-100,000/mm
3  50,000-74,999/mm 
3  25,000-49,999/mm 
3  < 25,000/mm
3 or diffuse 
petechiae 
Prothrombin time  15 - 19 sec.  20 - 22 sec.  23 - 45 sec.  > 45 sec. 
Activated partial 
thromboblastin time  37 - 61 sec.  62 - 86 sec.  87 - 111 sec.  > 111 sec. 
Serum Chemistries 
Sodium  130-< 131 mEq/L or 
148-150 mEq/L 
123-129 mEq/L or 
151-157 mEq/L 
116-122 mEq/L 
or 
158-165 mEq/L 
< 116 mEq/L or 
> 165 mEq/L 
Potassium  3.0-3.3 mEq/L or 
5.6-6.0 mEq/L 
2.5-2.9 mEq/L or 
6.1-6.5 mEq/L 
2.0-2.4 mEq/L or 
6.6-7.0 mEq/L 
< 2.0 mEq/L or 
> 7.0 mEq/L  
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Appendix 1:  Gilead Sciences Modified NIAID Common Toxicity Grading Scale (Continued) 
 
Serum Chemistries 
(Continued)  Grade 1  Grade 2  Grade 3  Grade 4 
Calcium  3.0-3.4 mg/dL or  2.5-2.9 mg/dL or  2.0-2.4 mg/dL or  < 2 mg/dL or 
(ionized)  5.6-6.0 mg/dL  6.1-6.5 mg/dL  6.6-7.0 mg/dL  > 7.0 mg/dL 
Calcium  7.8- < 8.4 mg/dL or  7.0-7.7 mg/dL or  6.1-6.9 mg/dL or  < 6.1 mg/dL or 
(corrected for albumin)  10.6-11.5 mg/dL  11.6-12.5 mg/dL  12.6-13.5 mg/dL  > 13.5 mg/dL 
Triglycerides  -----------------------  400-750 mg/dL  751-1200 mg/dL  > 1200 mg/dL 
Glucose  55-64 mg/dL or  40-54 mg/dL or  30-39 mg/dL or  < 30 mg/dL or 
  116-160 mg/dL  161-250 mg/dL  251-500 mg/dL  > 500 mg/dL 
Magnesium  1.0-< 1.2 mEq/L  0.9-< 1.0 mEq/L  N/A  N/A 
Phosphorus  2.0- < 2.2 mg/dL  1.5-1.9 mg/dL  1.0-1.4 mg/dL  < 1.0 mg/dL 
Bilirubin  1.3 - 1.8 mg/dL  1.9 - 3 mg/dL  3.1 - 6 mg/dL  > 6 mg/dL 
Bicarbonate  16 - < 17 mEq/L  11 - 15.9 mEq/L  8 - 10.9 mEq/L  < 8 mEq/L 
Creatinine  An increase > 0.5 mg/dL 
from  2.1-3.0 mg/dL  3.1-6.0 mg/dL  > 6.0 mg/dL 
  Baseline        
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Appendix 1:  Gilead Sciences Modified NIAID Common Toxicity Grading Scale (Continued) 
 
Serum Chemistries         
(Continued)  Grade 1  Grade 2  Grade 3  Grade 4 
BUN  30 - 60 mg/dL  61 - 120 mg/dL  121 - 240 mg/dL  > 240 mg/dL 
CK (unrelated to 
trauma, 
M: 248 - 498 U/L  M: 499 - 990 U/L  M: 991 - 1980 U/L  M: > 1980 U/L 
exercise, or IM 
injection)         
  F: 211 - 423 U/L  F: 424 - 845 U/L  F: 846 - 1690 U/L  F: > 1690 U/L 
For Patients With Normal LFTs at Baseline (< 2 x ULN) 
AST  M: 46 - 90 U/L  M: 91 - 180 U/L  M: 181 - 360 U/L  M: > 360 U/L 
  F: 43 - 85 U/L  F: 86 - 170 U/L  F: 171 - 340 U/L  F: > 340 U/L 
ALT  M: 54 - 108 U/L  M: 109- 215 U/L  M: 216 - 430 U/L  M: > 430 U/L 
  F: 43 - 85 U/L  F: 86 - 170 U/L  F: 171 - 340 U/L  F: > 340 U/L 
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Appendix 1: Gilead Sciences Modified NIAID Common Toxicity Grading Scale (Continued) 
 
For Patients With 
Normal 
LFTs at Baseline (< 
2 x ULN) 
(Continued) 
Grade 1  Grade 2  Grade 3  Grade 4 
Alkaline Phosphatase         
Female: 15 - 59 y  138 - 275 U/L  276 - 550 U/L  551 -1100 U/L  >1100 U/L 
>59 y  144- 288 U/L  289- 575 U/L  576- 1150 U/L  >1150 U/L 
Male: 15 - 20 y  313 - 625 U/L  626 - 1250 U/L  1251 - 2500 U/L  >2500 U/L 
21 - 59 y  138 - 275 U/L  276 - 550 U/L  551 - 1100 U/L  >1 100 U/L 
> 59 y  144 - 288 U/L  289 - 575 U/L  576 - 1150 U/L  >1150 U/L 
For Patients With Elevated LFTs at Baseline (> 2 x ULN) 
AST  M: 180- 252 U/L 
F: 170 - 238 U/L 
M: 253 - 360 U/L 
F: 239 - 340 U/L 
M: 361 - 540 U/L 
F: 341- 510 U/L 
M: > 540 U/L 
F: > 510 U/L 
ALT  M: 215 - 301 U/L 
F: 170 - 238 U/L 
M: 302- 430 U/L 
F: 239 - 340 U/L 
M: 431 - 645 U/L 
F: 341 - 510 U/L 
M: > 645 U/L 
F: > 510 U/L 
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Appendix 1: Gilead Sciences Modified NIAID Common Toxicity Grading Scale (Continued) 
 
For Patients 
With 
Elevated LFTs at 
Baseline (>_ 2 x 
ULN) 
(Continued) 
  Grade 1    Grade 2    Grade 3  Grade 4 
Alkaline Phosphatase         
Female: 15  - 59 y  550- 770 U/L  771- 1100 U/L  1101- 1650 U/L  > 1650 U/L 
  >59 y  575- 805 U/L  806- 1150 U/L  1151- 1725 U/L  >1725 U/L 
Male: 15  - 20 y  1250- 1750 U/L  1751- 2500 U/L  2501- 3750 U/L  >3750 U/L 
20  - 59 y  550- 770 U/L  771- 1100 U/L  1101- 1650 U/L  >1650 U/L 
  > 59 y  575- 805 U/L  806- 1150 U/L  1151- 1725 U/L  >1725 U/L 
Amylase    97- 131 U/L  132- 175 U/L  176- 439 U/L  > 440 
Lipase    1-60 yr:
> 60 yr:
154 - 210 U/L 
198 - 270 U/L 
1-60 yr:
> 60 yr:
211 - 279 U/L 
271 - 360 U/L 
1-60 yr:
> 60 yr:
280 - 699 U/L 
361 - 900 U/L 
1-60 yr: > 699 
> 60 yr: > 900 
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Appendix 1: Gilead Sciences Modified NIAID Common Toxicity Grading Scale (Continued) 
 
Urinalysis  Grade 1  Grade 2  Grade 3  Grade 4 
Proteinuria  1+; 30-99 mg/dL  2+ to 3+; 100-1000 
mg/dL  4+; > 1000 mg/dL  nephrotic syndrome 
Glycosuria  1+  2+  3+  4+ 
Hematuria  Microscopic only, 1-10 
RBCs 
gross hematuria without clots 
or 10-100 
gross hematuria with 
clots or > 
obstructive or Rx 
required 
    RBCs  101 RBCs or too 
numerous to   
      count   
Respiratory 
Dyspnea  Dyspnea on significant  dyspnea at normal level of 
activity  dyspnea at rest  requires ventilatory 
support 
  exertion       
Cardiac Function  ----------------------
- 
Symptoms with ordinary 
physical activity. 
Symptoms with less than 
ordinary 
Symptoms with any 
physical 
    Slight limitation of 
activity. 
physical activity. 
Marked 
activity or even at 
rest. 
      limitation of activity.   
Hypertension  20-25% increase from  26-30% increase from 
baseline systolic 
31-40% increase 
from baseline 
> 40% increase from 
baseline 
  baseline systolic    systolic  systolic 
Hypotension  20-25% decrease from  26-30% decrease from 
baseline systolic 
31-40% decrease 
from baseline 
> 40% decrease from 
baseline    baseline systolic  Systolic  systolic  systolic 
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Gastrointestinal  Grade 1  Grade 2  Grade 3  Grade 4 
Oral discomfort/ 
Stomatitis 
mild discomfort, no 
difficulty swallowing 
difficulty swallowing but 
able to eat and drink fluids 
unable to swallow 
solids 
unable to drink fluids; 
requires IV fluids 
Nausea  mild or transient, 
maintains 
moderate discomfort; some 
limitation of food 
severe discomfort; 
minimal food 
life threatening, unable 
to ingest 
  reasonable food 
intake 
intake  intake for 3 or more days  any food or fluid in 72 
hours 
Vomiting  mild or transient; 2-3 
episodes 
moderate or persistent; 4-5 
episodes in 24  severe; vomiting of all  life threatening 
hypotensive shock 
  in 24 hours OR 1-
2 episodes 
hours OR 1-2 episodes per day for 
> 1 week 
food/fluids in 24 hrs. OR   
  per day lasting < 1 
week    orthostatic hypotension   
Diarrhea  mild or transient, 
3-4 loose 
moderate or persistent, 5-7 loose 
stools in 24 
severe; bloody diarrhea 
or 8-9 
life threatening; 
hypotensive shock 
  stools/in 24 hours 
OR mild 
hours OR 3-4 loose stools per day 
> 1 week 
loose stools in 24 hours 
OR 
OR hospitalization for IV 
fluids 
  diarrhea lasting < 
1 week    orthostatic hypotension   
Abdominal Pain  mild, occasional 
transient 
moderate, transient, no or minimal 
Rx 
severe or requiring 
analgesic 
severe with guarding 
peritoneal 
    required    signs 
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Neuro/Neuromuscular  Grade 1  Grade 2  Grade 3  Grade 4 
(Continued)         
Neuro Cerebellar  Slight incoordination;  intention tremor; dysmetria; 
slurred speech; 
locomotor ataxia  incapacitated 
    nystagmus     
  dysdiadochokinesia       
Neuro-psych/Mood  Mild anxiety or mild 
depression 
therapy required for moderate 
anxiety or moderate 
needs assistance for 
severe anxiety or 
acute psychosis or 
incapacitated or 
    depression  severe depression or 
severe mania  hospitalization 
Muscle strength  Subjective weakness; 
no 
mild objective weakness; no 
decrease in function 
objective weakness; 
function limited  paralysis 
  objective symptoms       
Headache  mild; no therapy 
required 
moderate; non-narcotic analgesic 
therapy required 
severe; responds to 
initial narcotic 
intractable; requiring 
repeated 
      therapy  narcotic therapy 
Peripheral Neuropathy mild discomfort; no 
therapy 
moderate discomfort persisting for 
> 72 hours; 
severe discomfort; 
marked antalgic 
incapacitating; 
intolerable 
  required  non-narcotic analgesia required 
OR mild discomfort 
gait; narcotic analgesia 
required with 
discomfort; not improved 
OR 
    persisting for > 72 hours 
accompanied by loss of 
symptomatic improvement unable to walk despite 
narcotic 
    deep tendon reflex previously 
present    analgesia 
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Neuro/Neuromuscular 
(Continued) 
Grade 1  Grade 2  Grade 3  Grade 4 
Myositis  minimal findings  Patients must have some  Patients must have some  Patients must have some 
    (positive EMG or muscle 
biopsy) and one of the 
myositis (positive EMG or 
muscle 
myositis (positive EMG 
or muscle 
    following:  biopsy) and one of the 
following: 
biopsy) and one of the 
following: 
    1) mild to moderate muscle pain 
(myalgias) 
1) moderate to severe 
myalgias 
1) severe myalgias not 
related to      present > 4 weeks; may require 
nonsteroidal 
> 4 weeks requiring 
nonsteroidal 
exercise, requiring 
narcotics 
    anti-inflammatory drugs  anti-inflammatory drugs 
(NSAII)S)   
        2)muscle weakness 
resulting in      2) difficulty climbing stairs or 
rising from a 
2) needs some assistance 
with 
inability to ambulate, 
requiring 
    sitting position but able to 
ambulate without 
ambulation or general 
activities 
special care and 
assistance with 
    assistance    mobilization 
        3) acute rhabdomyolysis 
with          muscle necrosis and 
edema, 
        moderate to severe 
muscle weakness 
        with inability to ambulate 
or 
        mobilize without 
assistance          4) acute rhabdomyolysis 
associated 
        with electrolyte 
imbalance in renal 
        failure  
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Skin / Allergy  Grade 1  Grade 2  Grade 3  Grade 4 
Allergic reaction  pruritus without rash  localized urticaria  generalized urticaria, 
angioedema  anaphylaxis 
Local reaction  Erythema OR tenderness  induration < 10 mm or phlebitis 
or inflammation 
induration > l0mm or 
ulceration  necrosis of skin 
Cutaneous  Erythema OR pruritus  diffuse maculopapular rash, dry  vesiculation, moist  exfoliative dermatitis, 
      ulceration  membrane involvement, 
OR 
        Stevens-Johnson OR 
erythema 
        multiforme, OR necrosis 
requiring 
        surgery 
OTHER MEASUREMENTS 
Fever oral, (in absence 
of 
37.7-38.5°C or 100.0-
101.5°F 
38.6-39.5°C or 101.6-102.9°F  39.6-40.5°C or 103-1057  > 40.5°C or > 
105°F  infection) > 12 hrs.         
Fatigue  normal activity 
reduced < 25%  normal activity reduced 25-50%  normal activity reduced  unable to care for 
self 
      > 50%, cannot work   
Other toxicity not in 
table 
Transient or mild 
discomfort; 
mild-moderate impact on activity; 
requiring some 
marked impact on activity; 
requiring 
complete disability; 
requiring 
  requiring no limitation 
of activity; 
assistance and medical 
intervention 
some assistance and 
medical 
significant assistance and 
medical 
  no therapy    intervention  intervention and/or 
hospitalization 
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Other than creatinine elevation 
Grade 1 
(Mild) 
Grade 2 
(Moderate) 
Grade 3 
(Severe) 
Grade 4 
(Possibly Life-Threatening) 
May continue at the 
discretion of the 
Investigator 
Repeat lab to confirm 
toxicity grade 
Repeat lab to confirm 
toxicity grade 
 
If confirmed and 
possibly or probably 
related to study drugs, 
discontinue drugs 
permanently and 
follow at periodic 
intervals not less 
frequently than 
weekly until a return 
to baseline or is 
otherwise explained 
If confirmed and possibly and/or probably related 
to study drug 
 
1.  Withhold study drug until < Grad 2 
 
2.  Restart study drug  
If confirmed and 
unrelated to study drug,  
may continue at the 
discretion of the 
Investigator 
If Grade 3 or 4 recurrence that is confirmed and 
possibly or probably related to study drug, 
discontinue study drug permanently.  
If Grade 3 or 4 recurrence that is considered 
unrelated to study drug, continue study drug at the 
discretion of the Investigator.   
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APPENDIX 3: MANAGEMENT OF CREATININE ELEVATIONS 
Grade 1 
Increase > 0.5 mg/dL 
from Baseline 
(mild) 
Grade 2 
2.1-3.0 mg/dL 
(Moderate) 
Grade 3 
3.1-6.0 mg/dL 
 (Severe) 
Grade 4 
>6.0 mg/dL 
(Possibly Life-
Threatening) 
Repeat lab to confirm 
toxicity grade 
Repeat lab to confirm 
toxicity grade 
Repeat lab to confirm 
toxicity grade 
Repeat lab to confirm 
toxicity grade 
If confirmed  If confirmed  If confirmed  If confirmed 
May continue study 
drug.  Weekly 
monitoring is 
recommended until a 
return to within 0.3 
mg/dL of the baseline 
value. 
Discontinue study drug and follow at periodic intervals not less frequently than weekly 
until a return to within 0.3 mg/dL of baseline value.  
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APPENDIX 4: STUDY ACTIVITIES CHART 
 
Event  Screening  Enrollment  Follow-Up  Final Visit 
Informed consent  ￿  ￿  ￿  ￿ 
Eligibility criteria assessment  ￿  ￿  ￿   
Assign Participant ID number  ￿       
Pre-test HIV counseling  ￿  ￿  ￿  ￿ 
HIV test  ￿  ￿  ￿  ￿ 
Urine pregnancy test  ￿  ￿  ￿  ￿ 
Obtain contact information  ￿  ￿  ￿   
Physical  exam  ￿  (if indicated)  ￿ 
(months 1, 3, 
6, 9, 12) 
￿ 
Blood draw for labs  ￿    ￿ 
(months 1, 3, 
6, 9, 12) 
￿ 
Counseling for STI prevention  ￿  ￿  ￿  ￿ 
Interview  ￿  ￿  ￿  ￿ 
Post-test HIV counseling & test results  ￿  ￿  ￿  ￿ 
Randomization    ￿     
Product supplies given    ￿  ￿   
AE assessment      ￿  ￿ 
Concomitant medications  ￿  ￿  ￿  ￿ 
 
 
 